Liposomes Industry to 2034 - Recent Development
The global liposomes market is anticipated to reach a size of US$ 7.87 Bn in 2025. It is predicted to rise at a CAGR of 6% during the forecast period to reach a value of US$ 11.83 Bn by 2032. Liposome manufacturing is gaining importance in the biopharmaceutical industry to tackle drug development challenges like poor solubility and low permeability of active pharmaceutical ingredients (APIs). Liposomes, tiny vesicles with lipid bilayers, provide targeted drug delivery, enhancing treatment effectiveness and minimizing side effects. Consequently, making them valuable in therapeutic areas like cancer, genetic disorders, and infectious diseases. Recent Development • In June 2022, Endo Ventures Limited (EVL), a subsidiary of Endo International plc, acquired the clinical-stage private pharmaceutical company Taiwan Liposome Co., Ltd. signed an agreement with (TLC) will market TLC's research product, TLC599. TLC599...